Home » Stocks » AVXL

Anavex Life Sciences Corp. (AVXL)

Stock Price: $6.11 USD 0.36 (6.26%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $6.16 +0.05 (0.82%) Jan 22, 7:49 PM
Market Cap 409.14M
Revenue (ttm) n/a
Net Income (ttm) -26.28M
Shares Out 58.19M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $6.11
Previous Close $5.75
Change ($) 0.36
Change (%) 6.26%
Day's Open 5.70
Day's Range 5.68 - 6.15
Day's Volume 1,079,523
52-Week Range 2.38 - 7.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 days ago

Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear t...

Other stocks mentioned: BHVN, BIIB, LLY, SAVA
GlobeNewsWire - 2 weeks ago

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu...

Zacks Investment Research - 3 weeks ago

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 3 weeks ago

Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q4 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 weeks ago

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

GlobeNewsWire - 1 month ago

Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu...

The Motley Fool - 1 month ago

The company reported positive results from a phase 2 clinical trial.

Benzinga - 1 month ago

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the ...

Other stocks mentioned: MESO, BNTX, LLY, VTVT
GlobeNewsWire - 1 month ago

Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I

GlobeNewsWire - 1 month ago

Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Propert...

Insider Monkey - 1 month ago

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. M...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu...

GlobeNewsWire - 2 months ago

Statistically s ignificant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008)

Zacks Investment Research - 3 months ago

Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

The Motley Fool - 3 months ago

The biotech's drug appears to help patients with Parkinson's disease dementia.

GlobeNewsWire - 3 months ago

C linically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis

Seeking Alpha - 3 months ago

Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger th...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated thera...

GlobeNewsWire - 4 months ago

Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd An...

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...

Seeking Alpha - 5 months ago

Anavex Life Sciences Corp. (AVXL) CEO Dr.

GlobeNewsWire - 5 months ago

Conference Call and Webcast Today at 11:00 a.m. ET Conference Call and Webcast Today at 11:00 a.m. ET

GlobeNewsWire - 5 months ago

Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical St...

GlobeNewsWire - 5 months ago

Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time

Seeking Alpha - 6 months ago

Anavex Life Sciences is developing drugs for the treatment of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Rett Syndrome, fragile X, Angelman syndrome, and infantile spasms.

GlobeNewsWire - 6 months ago

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...

GlobeNewsWire - 6 months ago

NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...

Zacks Investment Research - 6 months ago

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 7 months ago

Is (AVXL) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 7 months ago

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...

Zacks Investment Research - 7 months ago

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 7 months ago

NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...

Zacks Investment Research - 7 months ago

Is (AVXL) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Anavex Life Sciences.

GlobeNewsWire - 8 months ago

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape...

Zacks Investment Research - 8 months ago

Anavex Life Sciences (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 8 months ago

Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Published in Alzheimer's & Dementia Journal, Results Highlight ANAVEX®2-73 (blarcamesine) Clinical Study, the First Reported Genome-Wide Search for Biomarkers Associated with Drug Response in ...

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor Anavex Life Sciences Corp.

Zacks Investment Research - 9 months ago

In the latest trading session, Anavex Life Sciences (AVXL) closed at $2.62, marking a -0.38% move from the previous day.

Seeking Alpha - 10 months ago

Anavex 2-72 And Neurological Disorders: A Possible Path Forward

Seeking Alpha - 10 months ago

Anavex 2-73 may be a peroxynitrite scavenger and as such may help in the treatment of various neurological conditions, including Rett syndrome, multiple sclerosis, and Alzheimer's disease.

The Motley Fool - 11 months ago

Can these soaring biotech stocks keep climbing?

Other stocks mentioned: ADAP, BTAI
Zacks Investment Research - 11 months ago

Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Benzinga - 11 months ago

By Harry Boxer, TheTechTrader These four stocks have strong technical momentum that could carry them higher.

Other stocks mentioned: LUNA, PRPL, TNDM
Seeking Alpha - 11 months ago

Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...

GlobeNewsWire - 11 months ago

NEW YORK, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...

About AVXL

Anavex Life Sciences, a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple scl... [Read more...]

Industry
Biotechnology
CEO
Christopher Missling
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
AVXL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 112.77% from the latest price.

Price Target
$13.00
(112.77% upside)
Analyst Consensus: Strong Buy